» Articles » PMID: 27536979

Effect of Sex and Age on Outcomes Among HIV-2-infected Patients Starting Antiretroviral Therapy in West Africa

Overview
Journal AIDS
Date 2016 Aug 19
PMID 27536979
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: HIV-2-infected individuals usually initiate antiretroviral therapy (ART) at an advanced age compared with HIV-1 patients, with a potential impact on treatment outcomes. This study aimed to investigate the effect of sex and age on mortality and loss to follow-up (LTFU) among HIV-2-infected individuals initiating ART.

Methods: Analyses were conducted using the database of the International Epidemiological Databases to Evaluate AIDS's collaboration in West Africa. LTFU was considered if the interval between the last visit and the closing date for this analysis was more than 180 days. Probability of death and LTFU were estimated with Kaplan-Meier methods. A Cox regression model was used to identify factors associated with death and LTFU over the first 24 months on ART.

Results: A total of 1825 HIV-2-infected individuals, including 60% women were considered for this analysis. The median age, baseline CD4 cell count, and follow-up duration were 45 years [interquartile range (IQR; 38-52)], 185 cells/μl [IQR (95-297)], and 28.8 months [IQR (9.8-58.9)], respectively. Over the first 24 months, the mortality rate was 5.2/100 person-years of observation [95% confidence interval (CI; 4.4-6.1)] and 469 (25.7%) were LTFU. Male sex [hazard ratio (HR) = 1.9; 95% CI (1.4; 2.8)], baseline CD4 cell count less than 100 cell/μl [HR = 4.4 95% CI (1.7; 11.1); ref at least 350 cell/μl], haemoglobin 7.5-10 g/dl [HR = 2.4 95% CI (1.3; 4.4); ref at least 12 g/dl], and BMI less than 18 kg/m [HR = 2.1 95% CI (1.3; 3.4); ref = 18-25 kg/m] were associated with higher mortality over the first 24 months. Similar associations were found for LTFU.

Conclusion: Mortality and LTFU are high among ART-receiving HIV-2-infected individuals and higher in men than in women. There is a critical need to further determine the causes of poor retention and implement sex-specific solutions that improve outcomes in HIV-2 ART programmes.

Citing Articles

Future of HIV2 and HIV2 +  1 Infected Patients Treated with Antiretrovirals Followed at the Day Hospital HIV Care Unit from 2011 to 2015.

Diallo I, Ouedraogo S, Sawadogo A, Ouedraogo G, Diendere E, Zoungrana J J Int Assoc Provid AIDS Care. 2022; 21:23259582221143675.

PMID: 36474417 PMC: 9732798. DOI: 10.1177/23259582221143675.


Does undernutrition increase the risk of lost to follow-up in adults living with HIV in sub-Saharan Africa? Protocol for a systematic review and meta-analysis.

Alebel A, Demant D, Petrucka P, Sibbritt D BMJ Open. 2021; 11(12):e048022.

PMID: 34907042 PMC: 8671928. DOI: 10.1136/bmjopen-2020-048022.


Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Raugi D, Ba S, Cisse O, Diallo K, Tamba I, Ndour C Clin Infect Dis. 2021; 72(3):369-378.

PMID: 33527119 PMC: 7850514. DOI: 10.1093/cid/ciaa277.


Effects of undernutrition on mortality and morbidity among adults living with HIV in sub-Saharan Africa: a systematic review and meta-analysis.

Alebel A, Demant D, Petrucka P, Sibbritt D BMC Infect Dis. 2021; 21(1):1.

PMID: 33390160 PMC: 7780691. DOI: 10.1186/s12879-020-05706-z.


Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.

Tchounga B, Charpentier C, Coffie P, Dabis F, Descamps D, Eholie S PLoS One. 2020; 15(8):e0236642.

PMID: 32756581 PMC: 7406077. DOI: 10.1371/journal.pone.0236642.


References
1.
Hogg R, Yip B, Chan K, Wood E, Craib K, OShaughnessy M . Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001; 286(20):2568-77. DOI: 10.1001/jama.286.20.2568. View

2.
Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R . Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1999; 1(7):457-68. View

3.
Ochieng-Ooko V, Ochieng D, Sidle J, Holdsworth M, Wools-Kaloustian K, Siika A . Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010; 88(9):681-8. PMC: 2930357. DOI: 10.2471/BLT.09.064329. View

4.
Braitstein P, Boulle A, Nash D, Brinkhof M, Dabis F, Laurent C . Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt). 2008; 17(1):47-55. DOI: 10.1089/jwh.2007.0353. View

5.
Honge B, Jespersen S, Nordentoft P, Medina C, Da Silva D, da Silva Z . Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open. 2013; 3(10):e003499. PMC: 3808780. DOI: 10.1136/bmjopen-2013-003499. View